Tools
Peters Anomaly
Introduction
Peters anomaly is a rare congenital disorder of the anterior segment of the eye.[1] It is named after Dr. Alfred Peters, a German ophthalmologist.[2] It is characterized by central corneal opacity of variable size with a corresponding defect in the posterior stroma, Descemet membrane, and endothelium.[3] The peripheral cornea is relatively clear, but a variable degree of haze may be associated with central opacity. In the Peters anomaly, the iridocorneal adhesions typically arise from the collarette and get attached to the margin of the corneal opacity.[4]
This iridocorneal adhesion can present as thin filaments, thick bands, or arcuate sheets. In 1974, Townsend et al. classified the Peters anomaly into three types. Type I involves the cornea alone and presents as a central corneal opacity. Type II presents with corneo-lenticular touch and corneal opacity. Type III has central corneal opacity with Rieger mesodermal dysgenesis.[5] Presently Peters anomaly is classified into two types.[3]
Type I has iridocorneal adhesion with corneal opacity. Type I predominantly involves one eye. Corneal opacity density varies from mild to severe with a clear peripheral cornea.[5] Sometimes peripheral corneal edema or scleralization may also be present.[6] Type I has fewer vitreoretinal and systemic abnormalities as compared to type II.[7] It has a good visual prognosis.[8] Type II has corneo-lenticular touch or corneal opacity with lens abnormalities.[9]
Type II most commonly presents bilaterally. In type II, the lens is directly adherent to the posterior corneal opacity. The lens is cataractous in type II, but it is in the center. The systemic association is more in type II patients. The term Peters-Plus syndrome was first proposed by VanSchooneveld et al. in 1984.[10]
If the Peters anomaly presents with systemic manifestations like cleft lip/palate, short stature, abnormal ears, and intellectual disability, it is called a Peters plus syndrome.[11] Krause-Kivlin syndrome is an autosomal recessive disorder, which has features of Peters anomaly, along with facial abnormalities, disproportionate short stature, and underdeveloped skeletal maturation.[12]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Peters anomaly commonly occurs as a sporadic disorder, but few inheritances patterns (autosomal dominant and autosomal recessive) have been noticed. Alteration in genes like the PAX6, PITX2, PITX3, COL4A1, FOXC1, and COL6A3 is responsible for the Peters anomaly.[13][14][15] PAX6 and FOXC1 are the most common gene mutations in the Peters anomaly. A study conducted by Vincent et al. in 2006 showed that 20% of cases of the Peters anomaly are due to mutation in CYP1B1.[16] Exposure to teratogens during the intrauterine growth period, intrauterine infection, and maternal alcoholism can also be causative factors in the Peters anomaly.[17]
PAX6
It is situated on chromosome 11p13. It has 14 exons, and it encodes a 422-amino acid protein.[18][19] PAX6 is a transcriptional factor that helps in the development of ocular tissue and the central nervous system. Mutations of the PAX6 gene lead to multiple ocular anomalies.[20] Ocular abnormalities due to mutation of the PAX6 gene include aniridia, Peters anomaly, congenital cataract, foveal hypoplasia, microphthalmia, morning glory disc anomaly, and optic nerve hypoplasia.[21][22][23][24]
FOXC1
It is a transcription factor situated at chromosome 6p25.[25] The missense mutation, nonsense mutation, frameshift mutation, and whole gene deletion of the FOXC1 gene lead to ocular, heart, and hearing defects. It has been implicated in the causation of anterior segment dysgenesis three and the type 3 Axenfeld-Rieger syndrome.
PITX2
It is situated on chromosome 4q25.[26] it is a homeodomain-containing transcription factor. PITX2 mutations and deletions lead to ocular, cardiac, and hearing defects.[27][28] PITX2 is estimated to be responsible for 40 % of Axenfeld-Rieger syndrome.[29][30] Diseases associated with a mutation in PITX2 include Axenfeld-Rieger syndrome, type 1; anterior segment dysgenesis 4; and ring dermoid of the cornea.
CYP1B1
The location of the gene is chromosome 2p22.2. Around 20% of cases of Peters anomaly are caused by the mutation of CYP1B1.
TFAP2A
It is a transcription factor situated at chromosome 6p24.3. Its response to retinoic acid is required for the normal development of the lens, optic cup, and craniofacial region. Mutation of this gene leads to branchiooculofacial syndrome.[31]
COL6A3
It is situated at the 2q37.3 chromosome and has 44 exons. This gene encodes the longest alpha three chains, which is needed for the firmness of collagen IV molecules. Collagen IV is amply expressed in the cornea.[32] The mutation of this gene leads to the retention of mutant protein in the endoplasmic reticulum (ER), and it further increases ER stress response. This leads to a decline in the resistance and cell variability to oxidative stress. The mutation of this gene may be noted in cases with isolated Peters anomaly.
CHD2 (chromodomain helicase DNA binding protein 2)
It is situated at chromosome 15q26.1. This gene encodes transmembrane protein N-cadherin. It is responsible for cell to cell adhesion. N cadherin protein is present in developing lens stalk and future corneal endothelium.[33]
DOP1B (DOP1 leucine zipper-like protein B)
It is situated at the 21q22 chromosome. This gene helps in protein-protein interaction. This gene may be responsible for autosomal recessive Peters anomaly in a consanguineous family.[34]
B3GLCT (β1,3-glucosyltransferase)
B3GLCT gene located on 13q12.3. This gene prompts the transfer of glucose to O-linked fucose on thrombospondin type-1 repeats (TSRs). Mutation of this gene leads to Peters plus syndrome (autosomal recessive).[35]
Other genes implicated in the Peters anomaly include PITX3, FOXE3, FLNA, HCCS, NDP, SLC4A11, and COL4A1.[14]
Epidemiology
Approximately 3.3 to 6.0 per 10,000 births have ocular malformation, of which the Peters anomaly forms a majority of the anterior segment malformation.[36] In the United States, 44 to 60 cases of Peters anomaly are reported annually.[37] In 80% of cases, it is bilateral but asymmetrical.[7] Around 50% of Peters Anomaly patients have ocular defects, and nearly 60% have systemic abnormalities.[38]
Pathophysiology
Neural crest cells (NCC) are multipotent cells and are extremely important for embryonic development.[39] Around the optic cup, these neural crest cells are termed periocular mesenchyme (POM).[40] NCCs cells migrate in three waves:
First Wave
In the first wave, neural crest cells pass between the anterior surface of the lens and the surface ectoderm. the first wave cells further differentiate into trabecular meshwork and corneal endothelium; this corneal endothelium will lead to form the Descemet membrane.[41]
Second Wave
Second wave neural crest cells are present between the corneal epithelium and endothelium. These cells further form corneal keratocytes of the corneal stroma.[41]
Third Wave
Neural crest cells in the third wave migrate to the angle between the corneal endothelium and the anterior edge of the optic cup. Third-wave cells differentiate into the iris stroma and ciliary body.[40]
The neural crest is responsible for developing an anterior segment of the eye, including the cornea, iris, sclera, ciliary body, trabecular meshwork, and aqueous outflow tracts. Any defect in the neural crest leads to anterior segment anomalies such as Axenfeld–Rieger syndrome and Peters anomaly. Peters anomaly occurs due to abnormal separation of lens vesicles from the surface ectoderm.[39]
Anterior Chamber Cleavage Syndrome
It is also called mesodermal dysgenesis of the iris and cornea. This syndrome includes three groups:
- Central
- Peripheral
- Central and peripheral components
Peripheral abnormalities include prominent Schwalbe line, attachment of iris strand to Schwalbe line, and anterior iris stromal hypoplasia. Central abnormalities include a central posterior corneal defect, central iridocorneal adhesion, and corneo-lenticular adhesion. Peters anomaly has also been called anterior chamber cleavage syndrome as it is associated with mesodermal dysgenesis of iris and posterior embryotoxon.[42]
Posterior Corneal Ulcer (Von Hippel’s Internal Corneal Ulcer)
It has corneal opacity associated with adherent iris and/or lens, along with signs of inflammation. Signs of inflammation differentiate it from Peters anomaly.[43]
Histopathology
Under a light microscope, the histological section shows the complete absence of endothelium and the Descemet membrane in the area of corneal opacity. The Bowman membrane may be thin or absent.[37] The cornea has proteoglycans, including Decorin, Keratan, and Lumican, which play essential roles in corneal development and transparency.[44]
Lumican is responsible for the posterior stromal collagen fibril arrangement and diameter. On lumican immunolabelling in Peters anomaly patients, there is a significant decrease in lumican level in the posterior corneal stroma.[45] This lumican deficiency seems to be responsible for larger and irregular development of the collagen bundle.[46]
The deficiency of decorin proteoglycan leads to corneal scarring.[47] Decorin staining intensity is significantly less in Peters anomaly cases than in normal corneal tissue. The major proteoglycan of the cornea is keratan sulfate. Keratan sulfate is responsible for maintaining the transparency and normal development of the cornea.[48] The immunolabelling intensity of keratan sulfate is less in Peters anomaly and congenital glaucoma.
History and Physical
It is important to discuss with the patient's family the duration of onset, nature of the progression of reduced vision, to take thorough maternal history regarding exposure to teratogens, alcohol intake, or any history of infection, and examine the eyes of parents and siblings for central corneal opacity.
Systemic and Ocular Examination
Generally, pediatricians first notice a central corneal opacity with abnormal red reflex. The central corneal opacity can vary in density and size with a relatively clear periphery and iridocorneal adhesion. In Peters anomaly type II, central corneal opacity and iridocorneal adhesion, lens abnormalities like cataracts are also present. In the bilateral cases of the Peters anomaly, the incidence of strabismus is higher.[49]
Peters anomaly may have nystagmus, microcornea, cornea plana, and glaucoma due to dysgenesis of the angle. Iris abnormalities, chorioretinal coloboma, retinal dysplasia, persistent hyperplastic primary vitreous, optic nerve hypoplasia, coloboma, and ptosis have also been associated.[50]
In the Peters anomaly, congenital glaucoma is present in 50 to 70% of cases. Raised intraocular pressure in peters anomaly is due to maldevelopment of trabecular meshwork and Schlemm's canal.[51] Congenital glaucoma usually presents within one year of birth but can be evident in childhood or even later.[52]
Screening for systemic abnormalities is also important. Systemic anomalies such as developmental delay, seizures disorder, central nervous system abnormalities, craniofacial abnormalities like cleft lip, cardiac malformation, and skeletal deformities may also be associated. Wilms tumor and linear skin defect are rare systemic associations that can present with the Peters anomaly.[53]
An abnormal corpus callosum and malformation of cortical development are common findings in brain imaging in patients with the Peters anomaly. In some cases, hypoplasia of the cerebellar vermis, cerebral calcification, and malformation of the hippocampus can be associated with the Peters anomaly.[54] Bilateral cases of Peters anomaly may have a higher rate (71.8%) of systemic abnormalities than unilateral cases of Peters anomaly.
Evaluation
Peters anomaly is diagnosed clinically, and investigations are done to characterize other abnormalities and document ocular abnormalities.
Ocular Investigations
Anterior Segment Photo
Anterior segment photo is useful for clinical, academic, and research purposes. The clinical picture helps with the following:
- Evaluating the accurate size, shape, and location of the lesion
- Comparing the condition of both eyes
- Explaining to the patients and their relatives about the condition
- Comparing preoperative and postoperative photos
- Teleconsultations[55]
Ultrasonography Brightness (USG B) SCAN
It helps in the evaluation of severity and diagnosis of the Peters anomaly.[54] B scan gives an idea about posterior segment abnormalities like retinal detachment or mass.
Ultrasound Biomicroscopy (UBM)
UBM is a noninvasive and diagnostic investigation for the Peters anomaly.[56] It uses a high frequency (50MHz), which provides a resolution axially up to 20 micrometers and 50 micrometers laterally, and the depth of tissue penetration is 4-5mm.[57]
At high resolution, it shows a shallow anterior chamber, iridocorneal adhesion, corneo-lenticular touch, hyperreflectivity at the posterior surface of the cornea, hyperechoic lens, and lens luxation.[56] It also detects early corneal edema and the absence of the Descemet membrane.[58] The 35 MHz probe has higher penetration and can visualize the ciliary body vividly.
Intraoperative OCT [iOCT, Spectral-domain OCT (SD-OCT)]
It is performed under anesthesia before corneal transplantation or during evaluation under anesthesia in a dark room. A total of 31 images of the limbal area were taken and analyzed in a study. It scans the central 6 mm cornea with an axial resolution of 5 micrometers.[59]
It helps in:
- Evaluation of anatomical features and severity
- Making the surgical decisions
The Peters anomaly was classified into three groups based on SD-OCT: mild, moderate, and severe.
Mild disease: It has irregular corneal thickness with defects in the Descemet membrane and the corneal endothelial layer with no iridocorneal adhesion. The anterior chamber angle is open.
Moderate disease: SD-OCT shows the irregular corneal thickness and iridocorneal adhesion. Iridocorneal adhesion can be present in one to three quadrants. A variable extent of anterior chamber angle closure is present.
Severe Disease: In this group, SD-OCT shows lenticulo-corneal adhesion with complete closure of all quadrants of the angle of the anterior chamber.[59]
Histological Investigation
It is useful in case of severe corneal opacity. It shows changes in every layer of the cornea. On histological examination, there is an absence of the Descemet membrane and endothelium at the site of corneal opacity. It shows disorderly arranged corneal stromal lamellae and iridocorneal adhesion.[60]
Radiological Investigation
A neurological investigation like MRI (magnetic resonance imaging) of the brain and orbit helps in detecting associated intracranial involvement and involvement of optic nerve. MRI orbit also helps differentiate long axial length due to coloboma, glaucoma, and axial myopia.[54]
Systemic Evaluation
- Echocardiography to rule out congenital abnormal development of the heart
- An abdominal ultrasound evaluation for renal malformation
- MRI and CT (computed tomography) scan of the brain and orbit to rule out cerebral and ocular involvement
Treatment / Management
In Peters anomaly patients, the main goal of management is to improve vision and prevent amblyopia. The management options include medical therapy or surgery.
Medical Management
Medical management includes occlusion therapy with or without mydriasis. Occlusion therapy is effective in mild cases only to prevent amblyopia.[49](B2)
Indications of occlusion therapy include:
- Corneal opacity that is not too dense and with visible fundus
- Unilateral corneal opacity in Peters anomaly
- Asymmetric bilateral corneal opacity
Medical management is also required to control intraocular pressure before and after glaucoma surgery.[61] However, medical management is not the definitive management of the Peters anomaly.(B2)
Surgical Management
Definitive treatment of the Peters anomaly is surgical, but the decision to perform surgery at a young age depends on multiple factors. The surgical intervention relies on the density of corneal opacity, the status of cornea, lens, and other ocular abnormalities.[61] (B2)
Surgical options include:
- A) Peripheral iridectomy: This can be done in cases where corneal opacity was limited with a clear periphery and a transparent lens.[62] Peripheral iridectomy is a safer technique and requires less postoperative care.[63] (B2)
- B) Penetrating keratoplasty with cataract extraction (if the lens is also involved).
Indications of penetrating keratoplasty include:
- Pupil occluding the corneal opacity even after dilation with a dilating agent
- Corneal opacity that is too dense with no view of the fundus
- Bilateral dense corneal opacity
Pediatric Keratoplasty Association conducted a survey and noticed that in infants, 65% of corneal grafts are done for Peters anomaly patients.[64] However, the success rate of grafts decreased to approximately 30 % after 5 to 10 years of surgery.[65]
The risk of Graft Failure increases in these cases:
- Larger and smaller grafts
- Anterior synechiae
- Central nervous system abnormality- Uncooperative patients may have poor postoperative care and compliance.[66]
- Young age
- An increased postoperative inflammatory response
- Other associated congenital ocular defects[67] (B2)
Keratoprostheses are indicated after multiple failed penetrating keratoplasties and in patients with severe corneal disease. The outcome of this intervention is very poor due to glaucoma, endophthalmitis, and retinal detachment.[65]
Glaucoma surgery, including trabeculectomy, diode laser cyclophotocoagulation, trabeculectomy with mitomycin C, and glaucoma drainage device, is generally performed. Primarily, the intraocular pressure can be controlled surgically, but adjunctive medical management may be required.
Differential Diagnosis
Differential diagnosis of congenital corneal opacity includes Sclerocornea, Trauma, Ulcer, Mucopolysaccharides, Peters anomaly, the Congenital Hereditary Endothelial Dystrophy, and corneal Dermoid. This can be remembered by the STUMPED acronym.[62]
Sclerocornea
It is not a very common disorder of anterior segment dysgenesis. Sclerocornea clinically presents as peripheral or complete corneal scleralization with loss of an identifiable limbus. If the entire cornea is involved, the central cornea is relatively clearer than the periphery. A 1 to 2 mm of the peripheral cornea is vascularized.[68] Other ocular abnormalities include shallow anterior chamber, iris deformities, and microphthalmos. Systemic abnormalities include limb abnormalities; and craniofacial and/or genitourinary malformation.
Tear in Descemet Membrane
Forceps-assisted delivery leads to birth trauma and causes clouding of the cornea due to rupture of the Descemet membrane. Rupture in the Descemet membrane due to forceps causes vertical Descemet tears, whereas, in congenital glaucoma, Horizontal or circumferential Haab's striae are present.[69] Other signs like peri-orbital ecchymosis and lid edema may be present.[70] Even after corneal haze is resolved, anisometropic astigmatism can develop and lead to severe amblyopia. Refractive error correction and patching may be required.[71]
Amniocentesis injury: This is an extremely rare condition that presents as unilateral angular or linear corneal opacity due to perforation by the needle. Along with corneal opacity, newborns may present with hyphema, corneal blood staining, raised intraocular pressure, iris and pupil deformity, and cataracts.[70]
Keratitis
Infectious cause like herpes simplex keratitis and bacterial keratitis is responsible for corneal opacity in newborns. Viral keratitis often presents within two weeks of birth. It is evident as cloudy cornea with the corneal epithelial defect.[70]
Corneal opacity is extremely rarely caused by congenital rubella. This infection is acquired in the first trimester of gestation. In rubella infection, corneal opacity occurs due to endotheliitis, raised intraocular pressure, or corneo-lenticular adhesion.[72]
Mucopolysaccharidosis
It is a lysosomal storage disorder inherited in an autosomal recessive manner. Clouding of the cornea occurs in the first year of life due to the accumulation of glycosaminoglycans.[73] Diffuse corneal opacity presents as bilaterally.[74] Other signs and symptoms include hypermetropia and astigmatism, keratoconjunctivitis sicca, glaucoma, retinopathy, and optic nerve head swelling. Corneal clouding is noted in MPS-IS (Schie). MPS-IH (Hurler), MPS-IV (Morquio), and MPS-VI (Maroteaux Lamy).
Other metabolic disorders like cystinosis and mucolipidosis IV are also responsible for corneal opacity in newborns.
Mucolipidosis IV: This condition is an extremely rare metabolic disorder that presents within a few weeks of birth. Corneal opacity and squint may be the first signs noted. Hospitalization is required due to severe psychomotor delay.[70]
Cystinosis: In cystinosis patients, elongated cystine crystals are deposited in the cornea due to a high cystine level. Crystals first deposit in the peripheral part of the cornea and the anterior stroma. Crystals deposits can be seen on the iris and ciliary body. Glaucoma can occur due to the deposition of crystals in the ciliary body. Other ophthalmic findings included astigmatism and bilateral hypopigmented retinopathy.[75]
Congenital Hereditary Endothelial Dystrophy (CHED)
CHED presents as diffuse corneal edema due to dysfunction of the corneal endothelium.CHED has a symmetrical thickening of the Descemet membrane in both eyes. CHED is autosomal recessive. In the 'IC3D Classification of Corneal Dystrophies—Edition 2', the so-called autosomal dominant CHED (previously called CHED1) has been reclassified under posterior polymorphous corneal dystrophy.[76] Corneal opacity differs in density from a blue-gray to complete corneal opacity. It is typically a bilateral process.[70]
Dermoid
It is a choristoma, mainly present in the epibulbar part, but sometimes it may involve the cornea and cover the visual axis.[77] Its size may vary. A large dermoid requires surgical intervention.[78]
Congenital Glaucoma
It can present as corneal haziness with raised intraocular pressure. Differentiating features of congenital glaucoma are buphthalmos, curvilinear Haab's striae, megalocornea, and optic disc cupping.[79]
Posterior polymorphous corneal dystrophy (PPCD)
It is an autosomal dominant disorder, usually reported in the second or third decade of life. In this disease, endothelium behaves like epithelial cells.[80] Its presentation ranges from linear, band-like, and grouped lesions. Epithelial cells may invade the angle of the anterior chamber and iris, causing raised intraocular pressure and irregular iris. It's a progressive disease, unlike CHED.[81] PPCD patients are at high risk of open and closed-angle glaucoma.[82]
Posterior Keratoconus
It is a rare corneal abnormality presenting as a local anterior bulging of posterior corneal curvature associated with stromal thinning.[83] Corneal haze in the posterior keratoconus is present in the center.[84] It is most frequently present unilaterally but can also be bilateral.[85]
Staging
Peters anomaly is divided into three grades based on the ocular structure involvement:
- Mild: Only cornea is involved, rest of iris and lens is normal.
- Moderate: There are iridocorneal adhesions or iris abnormalities like coloboma and iris atrophy.
- Severe: This is characterized by corneo-lenticular adhesion or corneal staphyloma with or without corneo-lenticular adhesion.[50]
Prognosis
Prognosis depends upon multiple factors like age of presentation, the severity of disease, and associated systemic abnormalities. Early surgical intervention like penetrating keratoplasty may prevent amblyopia, but it is associated with a high risk of graft failure. A study conducted by Rao et al. in 2005 suggested that only 22 % maintain clear grafts after two years of surgery.[67] Type I has a better visual prognosis than type II.[60]
Complications
The majority of complications in the Peters anomaly are present after penetrating keratoplasty. Postsurgical complication includes graft failure, glaucoma, cataract, retinal detachment, and phthisis.[86][87] Glaucoma is the most common complication present after surgery. Risk factors for complications include large donor grafts, multiple surgeries like lensectomy and vitrectomy, along with penetrating keratoplasty.[88] Non-surgical complications include amblyopia, nystagmus, and squint.
Deterrence and Patient Education
Genetic counseling and evaluation should be done in patients with Peters anomaly. The prognosis should be appropriately conveyed to the parents. The need for regular follow-up is paramount. The patients should receive education about the importance of compliance to therapy as the chances of amblyopia, glaucoma, squint, and other complications are high in these children.
Enhancing Healthcare Team Outcomes
The approach toward a child suffering from the Peters anomaly has to be extensive and collaborative. Early identification of this condition first by the treating pediatrician followed by prompt treatment by an ophthalmologist is required. Other associated systemic conditions such as developmental delay, seizure disorder, central nervous system malformations, craniofacial abnormalities like cleft lip, cardiac malformation, and skeletal deformities need interprofessional coordination among the various specialists, including an endocrinologist, cardiologists, pediatric surgeons, plastic surgeons, orthopedic surgeons, and a neurologist.
An interprofessional team approach is warranted to manage this condition, starting from early detection by the pediatrician and motivation for seeking advice from an ophthalmologist to prevent visual morbidity. It also involves validation of proper medication dosage and screening for drug interactions by the pharmacist, along with monitoring of vital signs, and parental education by the nurses. Visual evaluation by the optometrist is needed.
Subsequent counseling and education of the parents about various treatment options available for treating this condition by the ophthalmologist is crucial. Genetic counseling and evaluation play a vital role in managing patients with the Peters anomaly. Hence, this interprofessional teamwork plays a crucial role in the successful treatment of such newborns to improve the final outcome.
Media
(Click Image to Enlarge)
This is a clinical picture of the Peters anomaly a case, showing central corneal opacity with clear periphery. Anterior segment OCT shows increased corneal thickness.
Contributed by Prafulla Kumar Maharana, MD
References
Salik I, Gupta A, Tara A, Zaidman G, Barst S. Peters anomaly: A 5-year experience. Paediatric anaesthesia. 2020 May:30(5):577-583. doi: 10.1111/pan.13843. Epub 2020 Mar 16 [PubMed PMID: 32107814]
M S, V D, Punj J, Pandey R. Peters' anomaly - anaesthetic management. Indian journal of anaesthesia. 2009 Aug:53(4):501-3 [PubMed PMID: 20640218]
Alkatan HM, Al Dhaheri H, Al Harby M. Terminology of Peters' anomaly variants: Summary of histopathological findings in 6 corneas and detailed clinicopathological correlation in 2 cases. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. 2019 Jul-Sep:33(3):277-282. doi: 10.1016/j.sjopt.2018.02.015. Epub 2018 Mar 8 [PubMed PMID: 31686970]
Level 3 (low-level) evidenceYang LL, Lambert SR. Peters' anomaly. A synopsis of surgical management and visual outcome. Ophthalmology clinics of North America. 2001 Sep:14(3):467-77 [PubMed PMID: 11705147]
Almarzouki HS, Tayyib AA, Khayat HA, Alsulami RE, Alzahrani SM, Alkahtani AS, Alghifees LS. Peters Anomaly in Twins: A Case Report of a Rare Incident with Novel Comorbidities. Case reports in ophthalmology. 2016 Sep-Dec:7(3):186-192 [PubMed PMID: 27843434]
Level 3 (low-level) evidenceKenyon KR. Mesenchymal dysgenesis in Peter's anomaly, sclerocornea and congenital endothelial dystrophy. Experimental eye research. 1975 Aug:21(2):125-42 [PubMed PMID: 1100415]
Sault RW, Sheridan J. Peters' anomaly. Ophthalmology and eye diseases. 2013:5():1-3. doi: 10.4137/OED.S11142. Epub 2013 Feb 13 [PubMed PMID: 23650461]
Zaidman GW, Flanagan JK, Furey CC. Long-term visual prognosis in children after corneal transplant surgery for Peters anomaly type I. American journal of ophthalmology. 2007 Jul:144(1):104-108 [PubMed PMID: 17601429]
Level 2 (mid-level) evidenceBhandari R, Ferri S, Whittaker B, Liu M, Lazzaro DR. Peters anomaly: review of the literature. Cornea. 2011 Aug:30(8):939-44. doi: 10.1097/ICO.0b013e31820156a9. Epub [PubMed PMID: 21448066]
Level 3 (low-level) evidencevan Schooneveld MJ, Delleman JW, Beemer FA, Bleeker-Wagemakers EM. Peters'-plus: a new syndrome. Ophthalmic paediatrics and genetics. 1984 Dec:4(3):141-5 [PubMed PMID: 6443615]
Thompson EM, Winter RM, Baraitser M. Kivlin syndrome and Peters'-Plus syndrome: are they the same disorder? Clinical dysmorphology. 1993 Oct:2(4):301-16 [PubMed PMID: 7508317]
Frydman M, Weinstock AL, Cohen HA, Savir H, Varsano I. Autosomal recessive Peters anomaly, typical facial appearance, failure to thrive, hydrocephalus, and other anomalies: further delineation of the Krause-Kivlin syndrome. American journal of medical genetics. 1991 Jul 1:40(1):34-40 [PubMed PMID: 1887847]
Level 3 (low-level) evidenceReis LM, Semina EV. Genetics of anterior segment dysgenesis disorders. Current opinion in ophthalmology. 2011 Sep:22(5):314-24. doi: 10.1097/ICU.0b013e328349412b. Epub [PubMed PMID: 21730847]
Level 3 (low-level) evidenceWeh E, Reis LM, Happ HC, Levin AV, Wheeler PG, David KL, Carney E, Angle B, Hauser N, Semina EV. Whole exome sequence analysis of Peters anomaly. Human genetics. 2014 Dec:133(12):1497-511. doi: 10.1007/s00439-014-1481-x. Epub 2014 Sep 3 [PubMed PMID: 25182519]
Li Y, Zhang J, Dai Y, Fan Y, Xu J. Novel Mutations in COL6A3 That Associated With Peters' Anomaly Caused Abnormal Intracellular Protein Retention and Decreased Cellular Resistance to Oxidative Stress. Frontiers in cell and developmental biology. 2020:8():531986. doi: 10.3389/fcell.2020.531986. Epub 2020 Nov 10 [PubMed PMID: 33304895]
Vincent A, Billingsley G, Priston M, Glaser T, Oliver E, Walter M, Ritch R, Levin A, Heon E. Further support of the role of CYP1B1 in patients with Peters anomaly. Molecular vision. 2006 May 16:12():506-10 [PubMed PMID: 16735991]
Level 2 (mid-level) evidenceSebastiani G, Borrás-Novell C, Casanova MA, Pascual Tutusaus M, Ferrero Martínez S, Gómez Roig MD, García-Algar O. The Effects of Alcohol and Drugs of Abuse on Maternal Nutritional Profile during Pregnancy. Nutrients. 2018 Aug 2:10(8):. doi: 10.3390/nu10081008. Epub 2018 Aug 2 [PubMed PMID: 30072661]
Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, Jordan T, van Heyningen V, Hastie ND, Meijers-Heijboer H, Drechsler M. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell. 1991 Dec 20:67(6):1059-74 [PubMed PMID: 1684738]
Glaser T, Walton DS, Maas RL. Genomic structure, evolutionary conservation and aniridia mutations in the human PAX6 gene. Nature genetics. 1992 Nov:2(3):232-9 [PubMed PMID: 1345175]
Level 3 (low-level) evidenceJia X, Guo X, Jia X, Xiao X, Li S, Zhang Q. A novel mutation of PAX6 in Chinese patients with new clinical features of Peters' anomaly. Molecular vision. 2010 Apr 15:16():676-81 [PubMed PMID: 20405024]
Level 3 (low-level) evidenceDavis LK, Meyer KJ, Rudd DS, Librant AL, Epping EA, Sheffield VC, Wassink TH. Pax6 3' deletion results in aniridia, autism and mental retardation. Human genetics. 2008 May:123(4):371-8. doi: 10.1007/s00439-008-0484-x. Epub 2008 Mar 6 [PubMed PMID: 18322702]
Level 3 (low-level) evidenceVillarroel CE, Villanueva-Mendoza C, Orozco L, Alcántara-Ortigoza MA, Jiménez DF, Ordaz JC, González-del Angel A. Molecular analysis of the PAX6 gene in Mexican patients with congenital aniridia: report of four novel mutations. Molecular vision. 2008 Sep 8:14():1650-8 [PubMed PMID: 18776953]
Mihelec M, St Heaps L, Flaherty M, Billson F, Rudduck C, Tam PP, Grigg JR, Peters GB, Jamieson RV. Chromosomal rearrangements and novel genes in disorders of eye development, cataract and glaucoma. Twin research and human genetics : the official journal of the International Society for Twin Studies. 2008 Aug:11(4):412-21. doi: 10.1375/twin.11.4.412. Epub [PubMed PMID: 18637741]
Churchill AJ, Yeung A. A compound heterozygous change found in Peters' anomaly. Molecular vision. 2005 Jan 21:11():66-70 [PubMed PMID: 15682044]
Mears AJ, Jordan T, Mirzayans F, Dubois S, Kume T, Parlee M, Ritch R, Koop B, Kuo WL, Collins C, Marshall J, Gould DB, Pearce W, Carlsson P, Enerbäck S, Morissette J, Bhattacharya S, Hogan B, Raymond V, Walter MA. Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. American journal of human genetics. 1998 Nov:63(5):1316-28 [PubMed PMID: 9792859]
Level 3 (low-level) evidenceSemina EV, Reiter R, Leysens NJ, Alward WL, Small KW, Datson NA, Siegel-Bartelt J, Bierke-Nelson D, Bitoun P, Zabel BU, Carey JC, Murray JC. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nature genetics. 1996 Dec:14(4):392-9 [PubMed PMID: 8944018]
Level 3 (low-level) evidenceD'haene B, Meire F, Claerhout I, Kroes HY, Plomp A, Arens YH, de Ravel T, Casteels I, De Jaegere S, Hooghe S, Wuyts W, van den Ende J, Roulez F, Veenstra-Knol HE, Oldenburg RA, Giltay J, Verheij JB, de Faber JT, Menten B, De Paepe A, Kestelyn P, Leroy BP, De Baere E. Expanding the spectrum of FOXC1 and PITX2 mutations and copy number changes in patients with anterior segment malformations. Investigative ophthalmology & visual science. 2011 Jan 21:52(1):324-33. doi: 10.1167/iovs.10-5309. Epub 2011 Jan 21 [PubMed PMID: 20881294]
Strungaru MH, Dinu I, Walter MA. Genotype-phenotype correlations in Axenfeld-Rieger malformation and glaucoma patients with FOXC1 and PITX2 mutations. Investigative ophthalmology & visual science. 2007 Jan:48(1):228-37 [PubMed PMID: 17197537]
Level 2 (mid-level) evidenceTümer Z, Bach-Holm D. Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations. European journal of human genetics : EJHG. 2009 Dec:17(12):1527-39. doi: 10.1038/ejhg.2009.93. Epub 2009 Jun 10 [PubMed PMID: 19513095]
Level 3 (low-level) evidenceHjalt TA, Semina EV. Current molecular understanding of Axenfeld-Rieger syndrome. Expert reviews in molecular medicine. 2005 Nov 8:7(25):1-17 [PubMed PMID: 16274491]
Level 3 (low-level) evidenceBassett EA, Williams T, Zacharias AL, Gage PJ, Fuhrmann S, West-Mays JA. AP-2alpha knockout mice exhibit optic cup patterning defects and failure of optic stalk morphogenesis. Human molecular genetics. 2010 May 1:19(9):1791-804. doi: 10.1093/hmg/ddq060. Epub 2010 Feb 11 [PubMed PMID: 20150232]
Level 3 (low-level) evidenceLamandé SR, Sigalas E, Pan TC, Chu ML, Dziadek M, Timpl R, Bateman JF. The role of the alpha3(VI) chain in collagen VI assembly. Expression of an alpha3(VI) chain lacking N-terminal modules N10-N7 restores collagen VI assembly, secretion, and matrix deposition in an alpha3(VI)-deficient cell line. The Journal of biological chemistry. 1998 Mar 27:273(13):7423-30 [PubMed PMID: 9516440]
Reis LM, Houssin NS, Zamora C, Abdul-Rahman O, Kalish JM, Zackai EH, Plageman TF Jr, Semina EV. Novel variants in CDH2 are associated with a new syndrome including Peters anomaly. Clinical genetics. 2020 Mar:97(3):502-508. doi: 10.1111/cge.13660. Epub 2019 Nov 10 [PubMed PMID: 31650526]
Darbari E, Zare-Abdollahi D, Alavi A, Rezaei Kanavi M, Feizi S, Hosseini SB, Baradaran-Rafii A, Ahmadieh H, Issazadeh-Navikas S, Elahi E. A mutation in DOP1B identified as a probable cause for autosomal recessive Peters anomaly in a consanguineous family. Molecular vision. 2020:26():757-765 [PubMed PMID: 33273802]
Zhang A, Venkat A, Taujale R, Mull JL, Ito A, Kannan N, Haltiwanger RS. Peters plus syndrome mutations affect the function and stability of human β1,3-glucosyltransferase. The Journal of biological chemistry. 2021 Jul:297(1):100843. doi: 10.1016/j.jbc.2021.100843. Epub 2021 May 28 [PubMed PMID: 34058199]
Ni W, Wang W, Hong J, Zhang P, Liu C. A novel histopathologic finding in the Descemet's membrane of a patient with Peters Anomaly: a case-report and literature review. BMC ophthalmology. 2015 Oct 23:15():139. doi: 10.1186/s12886-015-0131-y. Epub 2015 Oct 23 [PubMed PMID: 26496717]
Level 3 (low-level) evidenceKuper C, Kuwabara T, Stark WJ. The histopathology of Peters' anomaly. American journal of ophthalmology. 1975 Oct:80(4):653-60 [PubMed PMID: 1180307]
Level 3 (low-level) evidenceTraboulsi EI, Maumenee IH. Peters' anomaly and associated congenital malformations. Archives of ophthalmology (Chicago, Ill. : 1960). 1992 Dec:110(12):1739-42 [PubMed PMID: 1463415]
Williams AL, Bohnsack BL. The Ocular Neural Crest: Specification, Migration, and Then What? Frontiers in cell and developmental biology. 2020:8():595896. doi: 10.3389/fcell.2020.595896. Epub 2020 Dec 23 [PubMed PMID: 33425902]
Williams AL, Bohnsack BL. Neural crest derivatives in ocular development: discerning the eye of the storm. Birth defects research. Part C, Embryo today : reviews. 2015 Jun:105(2):87-95. doi: 10.1002/bdrc.21095. Epub 2015 Jun 4 [PubMed PMID: 26043871]
Gage PJ, Rhoades W, Prucka SK, Hjalt T. Fate maps of neural crest and mesoderm in the mammalian eye. Investigative ophthalmology & visual science. 2005 Nov:46(11):4200-8 [PubMed PMID: 16249499]
Level 3 (low-level) evidenceWaring GO 3rd, Rodrigues MM, Laibson PR. Anterior chamber cleavage syndrome. A stepladder classification. Survey of ophthalmology. 1975 Jul-Aug:20(1):3-27 [PubMed PMID: 808872]
Level 3 (low-level) evidenceTownsend WM. Congenital corneal leukomas. 1. Central defect in Descemet's membrane. American journal of ophthalmology. 1974 Jan:77(1):80-6 [PubMed PMID: 4824179]
Hassell JR, Birk DE. The molecular basis of corneal transparency. Experimental eye research. 2010 Sep:91(3):326-35. doi: 10.1016/j.exer.2010.06.021. Epub 2010 Jul 3 [PubMed PMID: 20599432]
Level 3 (low-level) evidenceAl Shamrani M, Al Hati K, Alkatan H, Alharby M, Jastaneiah S, Song J, Edward DP. Pathological and Immunohistochemical Alterations of the Cornea in Congenital Corneal Opacification Secondary to Primary Congenital Glaucoma and Peters Anomaly. Cornea. 2016 Feb:35(2):226-33. doi: 10.1097/ICO.0000000000000705. Epub [PubMed PMID: 26684044]
Chakravarti S, Zhang G, Chervoneva I, Roberts L, Birk DE. Collagen fibril assembly during postnatal development and dysfunctional regulation in the lumican-deficient murine cornea. Developmental dynamics : an official publication of the American Association of Anatomists. 2006 Sep:235(9):2493-506 [PubMed PMID: 16786597]
Level 3 (low-level) evidenceChen S, Birk DE. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. The FEBS journal. 2013 May:280(10):2120-37. doi: 10.1111/febs.12136. Epub 2013 Feb 14 [PubMed PMID: 23331954]
Level 3 (low-level) evidenceQuantock AJ, Young RD, Akama TO. Structural and biochemical aspects of keratan sulphate in the cornea. Cellular and molecular life sciences : CMLS. 2010 Mar:67(6):891-906. doi: 10.1007/s00018-009-0228-7. Epub [PubMed PMID: 20213925]
Level 3 (low-level) evidenceNajjar DM, Christiansen SP, Bothun ED, Summers CG. Strabismus and amblyopia in bilateral Peters anomaly. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2006 Jun:10(3):193-7 [PubMed PMID: 16814168]
Level 2 (mid-level) evidenceYang LL, Lambert SR, Lynn MJ, Stulting RD. Long-term results of corneal graft survival in infants and children with peters anomaly. Ophthalmology. 1999 Apr:106(4):833-48 [PubMed PMID: 10201611]
Level 2 (mid-level) evidenceYang LL, Lambert SR, Lynn MJ, Stulting RD. Surgical management of glaucoma in infants and children with Peters' anomaly: long-term structural and functional outcome. Ophthalmology. 2004 Jan:111(1):112-7 [PubMed PMID: 14711722]
Level 2 (mid-level) evidenceWalton DS. Primary congenital open angle glaucoma: a study of the anterior segment abnormalities. Transactions of the American Ophthalmological Society. 1979:77():746-68 [PubMed PMID: 545836]
Eiferman RA. Association of Wilms' tumor with Peter's anomaly. Annals of ophthalmology. 1984 Oct:16(10):933-4 [PubMed PMID: 6095719]
Level 3 (low-level) evidenceSamara A, Eldaya RW. Ocular and brain imaging findings in Peters' anomaly: A case report and literature review. Radiology case reports. 2020 Jul:15(7):863-866. doi: 10.1016/j.radcr.2020.04.011. Epub 2020 Apr 30 [PubMed PMID: 32382368]
Level 3 (low-level) evidenceBhattacharya S. Clinical photography and our responsibilities. Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India. 2014 Sep-Dec:47(3):277-80. doi: 10.4103/0970-0358.146569. Epub [PubMed PMID: 25593409]
Haddad AM, Greenfield DS, Stegman Z, Liebmann JM, Ritch R. Peter's anomaly: diagnosis by ultrasound biomicroscopy. Ophthalmic surgery and lasers. 1997 Apr:28(4):311-2 [PubMed PMID: 9101570]
Level 3 (low-level) evidenceChen WS, Xiang DM, Hu LX. Ultrasound Biomicroscopy Detects Peters' Anomaly and Rieger's Anomaly in Infants. Journal of ophthalmology. 2020:2020():8346981. doi: 10.1155/2020/8346981. Epub 2020 Mar 23 [PubMed PMID: 32280536]
Myles WM, Flanders ME, Chitayat D, Brownstein S. Peters' anomaly: a clinicopathologic study. Journal of pediatric ophthalmology and strabismus. 1992 Nov-Dec:29(6):374-81 [PubMed PMID: 1287176]
Level 3 (low-level) evidenceHong J, Yang Y, Cursiefen C, Mashaghi A, Wu D, Liu Z, Sun X, Dana R, Xu J. Optimising keratoplasty for Peters' anomaly in infants using spectral-domain optical coherence tomography. The British journal of ophthalmology. 2017 Jun:101(6):820-827. doi: 10.1136/bjophthalmol-2016-308658. Epub 2016 Sep 22 [PubMed PMID: 27660330]
Chang RQ, Du Y, Zhu XJ, Lu Y. Type II Peter's anomaly with histopathological proof: a case report. BMC ophthalmology. 2017 Jun 29:17(1):110. doi: 10.1186/s12886-017-0502-7. Epub 2017 Jun 29 [PubMed PMID: 28662686]
Level 3 (low-level) evidenceChang JW, Kim JH, Kim SJ, Yu YS. Long-term clinical course and visual outcome associated with Peters' anomaly. Eye (London, England). 2012 Sep:26(9):1237-42. doi: 10.1038/eye.2012.128. Epub 2012 Jun 29 [PubMed PMID: 22744393]
Level 2 (mid-level) evidenceMiao S, Lin Q, Liu Y, Song YW, Zhang YN, Pan ZQ. Clinicopathologic Features and Treatment Characteristics of Congenital Corneal Opacity Infants and Children Aged 3 Years or Less: A Retrospective Single Institution Analysis. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2020:29(1):18-24. doi: 10.1159/000501763. Epub 2019 Jun 28 [PubMed PMID: 31247621]
Level 2 (mid-level) evidenceSpierer O, Cavuoto KM, Suwannaraj S, McKeown CA, Chang TC. Outcome of optical iridectomy in Peters anomaly. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2018 Sep:256(9):1679-1683. doi: 10.1007/s00417-018-4000-2. Epub 2018 Apr 28 [PubMed PMID: 29705837]
Elbaz U, Strungaru H, Mireskandari K, Stephens D, Ali A. Long-Term Visual Outcomes and Clinical Course of Patients With Peters Anomaly. Cornea. 2021 Jul 1:40(7):822-830. doi: 10.1097/ICO.0000000000002577. Epub [PubMed PMID: 33156080]
Dolezal KA, Besirli CG, Mian SI, Sugar A, Moroi SE, Bohnsack BL. Glaucoma and Cornea Surgery Outcomes in Peters Anomaly. American journal of ophthalmology. 2019 Dec:208():367-375. doi: 10.1016/j.ajo.2019.08.012. Epub 2019 Aug 28 [PubMed PMID: 31470000]
Kurilec JM, Zaidman GW. Incidence of Peters anomaly and congenital corneal opacities interfering with vision in the United States. Cornea. 2014 Aug:33(8):848-50. doi: 10.1097/ICO.0000000000000182. Epub [PubMed PMID: 24977984]
Rao KV, Fernandes M, Gangopadhyay N, Vemuganti GK, Krishnaiah S, Sangwan VS. Outcome of penetrating keratoplasty for Peters anomaly. Cornea. 2008 Aug:27(7):749-53. doi: 10.1097/ICO.0b013e31816fe9a7. Epub [PubMed PMID: 18650657]
Level 2 (mid-level) evidenceKurji K, Damji K. Ophthaproblem. Can you identify this condition? Primary congenital glaucoma. Canadian family physician Medecin de famille canadien. 2012 Apr:58(4):409, 412-3 [PubMed PMID: 22499817]
Level 3 (low-level) evidenceAlobaidy R, Srinivasan S. Forceps-induced birth injury to the cornea. BMJ case reports. 2014 Apr 9:2014():. doi: 10.1136/bcr-2013-201786. Epub 2014 Apr 9 [PubMed PMID: 24717592]
Level 3 (low-level) evidenceNischal KK. A new approach to the classification of neonatal corneal opacities. Current opinion in ophthalmology. 2012 Sep:23(5):344-54. doi: 10.1097/ICU.0b013e328356893d. Epub [PubMed PMID: 22871880]
Level 3 (low-level) evidenceAgarwal R, Singh NK, Sinha R, Sharma N. Obstetrical forceps-induced Descemet membrane tears. Indian journal of ophthalmology. 2021 Dec:69(12):3432-3441. doi: 10.4103/ijo.IJO_863_21. Epub [PubMed PMID: 34826970]
Vijayalakshmi P, Rajasundari TA, Prasad NM, Prakash SK, Narendran K, Ravindran M, Muthukkaruppan VR, Lalitha P, Brown DW. Prevalence of eye signs in congenital rubella syndrome in South India: a role for population screening. The British journal of ophthalmology. 2007 Nov:91(11):1467-70 [PubMed PMID: 17947267]
Tomatsu S, Pitz S, Hampel U. Ophthalmological Findings in Mucopolysaccharidoses. Journal of clinical medicine. 2019 Sep 14:8(9):. doi: 10.3390/jcm8091467. Epub 2019 Sep 14 [PubMed PMID: 31540112]
Smith JA, Chan CC, Goldin E, Schiffmann R. Noninvasive diagnosis and ophthalmic features of mucolipidosis type IV. Ophthalmology. 2002 Mar:109(3):588-94 [PubMed PMID: 11874766]
Bose S, Yeo DCM, Wijetilleka S. Using two smartphones to look for corneal cystine crystals. Digital journal of ophthalmology : DJO. 2019 Jan:25(1):12-15. doi: 10.5693/djo.02.2019.02.003. Epub 2019 Mar 29 [PubMed PMID: 31080371]
Weiss JS, Møller HU, Aldave AJ, Seitz B, Bredrup C, Kivelä T, Munier FL, Rapuano CJ, Nischal KK, Kim EK, Sutphin J, Busin M, Labbé A, Kenyon KR, Kinoshita S, Lisch W. IC3D classification of corneal dystrophies--edition 2. Cornea. 2015 Feb:34(2):117-59. doi: 10.1097/ICO.0000000000000307. Epub [PubMed PMID: 25564336]
Henkind P, Marinoff G, Manas A, Friedman A. Bilateral corneal dermoids. American journal of ophthalmology. 1973 Dec:76(6):972-7 [PubMed PMID: 4759856]
Pirouzian A. Management of pediatric corneal limbal dermoids. Clinical ophthalmology (Auckland, N.Z.). 2013:7():607-14. doi: 10.2147/OPTH.S38663. Epub 2013 Mar 28 [PubMed PMID: 23576860]
Khan AO, Aldahmesh MA, Alkuraya F. Congenital hereditary endothelial dystrophy, not glaucoma, in a child with iris colobomas. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2016 Aug:20(4):370-2. doi: 10.1016/j.jaapos.2016.03.017. Epub 2016 Jun 29 [PubMed PMID: 27373217]
Goshe JM, Li JY, Terry MA. Successful Descemet's stripping automated endothelial keratoplasty for congenital hereditary endothelial dystrophy in a pediatric patient. International ophthalmology. 2012 Feb:32(1):61-6. doi: 10.1007/s10792-011-9511-3. Epub 2012 Jan 25 [PubMed PMID: 22274756]
Level 3 (low-level) evidenceDavidson AE, Liskova P, Evans CJ, Dudakova L, Nosková L, Pontikos N, Hartmannová H, Hodaňová K, Stránecký V, Kozmík Z, Levis HJ, Idigo N, Sasai N, Maher GJ, Bellingham J, Veli N, Ebenezer ND, Cheetham ME, Daniels JT, Thaung CM, Jirsova K, Plagnol V, Filipec M, Kmoch S, Tuft SJ, Hardcastle AJ. Autosomal-Dominant Corneal Endothelial Dystrophies CHED1 and PPCD1 Are Allelic Disorders Caused by Non-coding Mutations in the Promoter of OVOL2. American journal of human genetics. 2016 Jan 7:98(1):75-89. doi: 10.1016/j.ajhg.2015.11.018. Epub 2015 Dec 31 [PubMed PMID: 26749309]
Elhusseiny AM, Saeed HN. Posterior Polymorphous Corneal Dystrophy in a Pediatric Population. Cornea. 2022 Jun 1:41(6):734-739. doi: 10.1097/ICO.0000000000002847. Epub 2021 Aug 30 [PubMed PMID: 34469341]
Suwa Y, Matsuda M, Kinoshita S. [Two cases of posterior keratoconus]. Nippon Ganka Gakkai zasshi. 1991 May:95(5):500-3 [PubMed PMID: 1872224]
Level 3 (low-level) evidenceSilas MR, Hilkert SM, Reidy JJ, Farooq AV. Posterior keratoconus. The British journal of ophthalmology. 2018 Jul:102(7):863-867. doi: 10.1136/bjophthalmol-2017-311097. Epub 2017 Nov 9 [PubMed PMID: 29122822]
Vargas V, Alió J. Posterior keratoconus-clinical aspects and anterior segment optical coherence tomography findings: A case report. European journal of ophthalmology. 2019 Jan:29(1):NP1-NP5. doi: 10.1177/1120672118787436. Epub 2018 Jul 24 [PubMed PMID: 30039710]
Level 3 (low-level) evidencePatel HY, Ormonde S, Brookes NH, Moffatt LS, McGhee CN. The indications and outcome of paediatric corneal transplantation in New Zealand: 1991-2003. The British journal of ophthalmology. 2005 Apr:89(4):404-8 [PubMed PMID: 15774913]
Dana MR, Schaumberg DA, Moyes AL, Gomes JA. Corneal transplantation in children with Peters anomaly and mesenchymal dysgenesis. Multicenter Pediatric Keratoplasty Study. Ophthalmology. 1997 Oct:104(10):1580-6 [PubMed PMID: 9331194]
Level 2 (mid-level) evidenceDonoso Rojas R, Jara Urrutia G, López Garin JP. Long-term Experience and Visual Acuity Outcomes in Patients With Peters Anomaly. Journal of pediatric ophthalmology and strabismus. 2021 Sep-Oct:58(5):304-310. doi: 10.3928/01913913-20210412-01. Epub 2021 Sep 1 [PubMed PMID: 34592113]